In much of Europe, regulators have approved disease-modifying treatments for Alzheimer’s disease — but payers haven’t followed. Next week, @hilaryevansnewton.bsky.social chairs a WDC dialogue on what it will take to change that. Learn more: bit.ly/4seP96q
